Valuation: 4basebio PLC

Market Cap 87.4M 116M 102M 96.36M 164M 11.12B 165M 1.15B 444M 5.68B 435M 425M 18.23B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 87.99M 117M 103M 97M 165M 11.19B 166M 1.16B 447M 5.71B 437M 428M 18.36B EV / Sales 2026 *
85.8x
EV / Sales 2027 * 22.9x
Free-Float
38.75%
Yield 2026 *
-
Yield 2027 * -
1 week+17.19%
Current month+18.42%
1 month+18.42%
3 months+7.14%
6 months+10.29%
Current year-8.54%
1 week 550
Extreme 550
575
1 month 450
Extreme 450
575
Current year 420
Extreme 420
630
1 year 420
Extreme 420
820
3 years 420
Extreme 420
1,820
5 years 390
Extreme 390
1,820
10 years 175
Extreme 175
1,820
Manager TitleAgeSince
Chief Executive Officer 33 2026-02-09
Chief Tech/Sci/R&D Officer - 2025-02-28
Chief Operating Officer - 2026-03-11
Director TitleAgeSince
Director/Board Member 48 2020-12-21
Director/Board Member 33 2024-08-07
Chairman 60 2025-07-07
Date Insider Type Main position Quantity % Market Cap. Importance
5/21/26 Buy

Chief Executive Officer

1,863 0.0120%
2/16/26 Buy

Chief Executive Officer

2,650 0.0171%
2/11/26 Buy

Director

3,000 0.0193%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+17.19%-22.41%+0.90% 116M
+2.64%+7.07%+11.87%+38.40% 47.97B
+0.22%+1.71%+50.91%+34.00% 44.5B
-1.58%+5.65%+359.34%+598.06% 43.93B
+1.70%+4.61%+12.56%+90.97% 41.03B
+0.51%-0.61%+5.18%+46.87% 29.85B
-0.48%+0.59%+23.98%+148.36% 17.27B
+0.08%+9.30%+8.41% - 15.34B
+1.76%+2.98%+29.13%+45.78% 15.3B
+1.97%-2.82% - - 14.82B
Average +0.62%+3.94%+53.22%+125.42% 27.01B
Weighted average by Cap. +0.71%+2.98%+79.42%+158.45%

Financials

2026 *2027 *
Net sales 1.02M 1.36M 1.19M 1.13M 1.93M 130M 1.94M 13.53M 5.21M 66.57M 5.1M 4.99M 214M 5M 6.63M 5.82M 5.51M 9.39M 636M 9.44M 65.98M 25.42M 325M 24.86M 24.34M 1.04B
Net income -18.2M -24.13M -21.2M -20.06M -34.19M -2.31B -34.37M -240M -92.51M -1.18B -90.48M -88.59M -3.8B -
Net Debt 584K 775K 681K 644K 1.1M 74.35M 1.1M 7.71M 2.97M 37.96M 2.91M 2.85M 122M 27.1M 35.92M 31.57M 29.88M 50.91M 3.45B 51.18M 358M 138M 1.76B 135M 132M 5.65B
Logo 4basebio PLC
4basebio PLC is a United Kingdom-based life biotechnology company. The Company is focused on the development of advanced therapy medicinal products (ATMPs) through its synthetic Deoxyribonucleic acid (DNA) products and non-viral, cell-targeting nucleic acid delivery platform. The Company offers application-specific DNA constructs tailored to the diverse needs of gene therapies, genome editing, mRNA production, and DNA vaccines. Its synthetic DNA is produced via an enzymatic, cell-free manufacturing process. It utilizes a technology for primer-free DNA amplification called TruePrime, which enables high-yield and quality DNA production. By combining two enzymes, Trueprime technology achieves isothermal multiple displacement DNA amplification in a continuous cell-free process with high fidelity. The Company offers application-specific synthetic DNA solutions across mRNA vaccines and therapies, viral vectors, gene editing, DNA vaccines and non-viral delivery.
Employees
140
Date Price Change Volume
26-09-28 GBX 562.50 0.00% 2,082
26-09-25 GBX 562.50 0.00% 0
26-09-24 GBX 562.50 0.00% 64
26-09-23 GBX 562.50 0.00% 1,291
26-09-22 GBX 562.50 +1.35% 3,442
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
5.625GBP
Average target price
14.00GBP
Spread / Average Target
+148.89%

Annual profits - Rate of surprise